Scheper R J, Broxterman H J, Scheffer G L, Kaaijk P, Dalton W S, van Heijningen T H, van Kalken C K, Slovak M L, de Vries E G, van der Valk P
Department of Pathology, Free University Hospital, Amsterdam, The Netherlands.
Cancer Res. 1993 Apr 1;53(7):1475-9.
A M(r) 110,000 protein (p110) is overexpressed in P-glycoprotein-negative multidrug-resistant tumor cell lines of different histogenetic origins. These cell lines show an ATP-dependent drug accumulation defect, suggesting the presence of drug transporter molecules different from P-glycoprotein. Immunohistochemical staining with a p110-specific monoclonal antibody (LRP-56) showed that, like P-glycoprotein, the molecule has a high expression in normal epithelial cells and tissues chronically exposed to xenobiotics and potentially toxic agents, such as bronchial cells, cells lining the intestines, and kidney tubules. Staining of LRP-56 is primarily cytoplasmic, in a coarsely granular fashion, indicating that it reacts with a molecule closely associated with vesicular/lysosomal structures. Involvement of p110 in the energy-dependent drug transport process present in the cell lines is unknown.
一种分子量为110,000的蛋白质(p110)在不同组织发生起源的P-糖蛋白阴性多药耐药肿瘤细胞系中过表达。这些细胞系表现出ATP依赖性药物蓄积缺陷,提示存在不同于P-糖蛋白的药物转运分子。用p110特异性单克隆抗体(LRP-56)进行免疫组织化学染色显示,与P-糖蛋白一样,该分子在长期暴露于异生物素和潜在毒性剂的正常上皮细胞和组织中高表达,如支气管细胞、肠黏膜细胞和肾小管。LRP-56染色主要位于细胞质,呈粗颗粒状,表明它与一种与囊泡/溶酶体结构密切相关的分子发生反应。p110是否参与细胞系中存在的能量依赖性药物转运过程尚不清楚。